Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10953282 | 0.81 | CD44 (0.33) | CD44CYP3A4 | |
| SCHEMBL5089492 | 0.81 | CD44 (0.33) | CD44CYP3A4 | |
| SCHEMBL395548 | 0.78 | CYP3A4 (0.35) | CYP3A4 | |
| SCHEMBL28040852 | 0.76 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL16051567 | 0.74 | — | — | |
| SCHEMBL6544922 | 0.74 | HSD17B10 (0.42) | CYP3A4CHRM1ALOX15MAOATBXA2R | |
| SCHEMBL28823633 | 0.73 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL16858712 | 0.69 | RAPGEF4 (0.34) | — | |
| SCHEMBL28212398 | 0.69 | — | — | |
| SCHEMBL120848 | 0.68 | CD44 (0.61) | CD44CYP3A4CHRM1ALOX15MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210284653-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-10941159-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200095259-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10336769-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-8952161-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140024665-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2014-01-23 | — | — | US | disclosed |
| US-8084614-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CD44 4649/4885CYP3A4 1751/4885CHRM1 304/4885 |
| US-20210284653-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CD44 4649/4885CYP3A4 1751/4885CHRM1 304/4885 |
| US-10941159-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CD44 4649/4885CYP3A4 1751/4885CHRM1 304/4885 |
| US-20140024665-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CD44 4649/4885CYP3A4 1751/4885CHRM1 304/4885 |
| US-20200095259-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CD44 4649/4885CYP3A4 1751/4885CHRM1 304/4885 |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | CD44 4658/4885CYP3A4 1769/4885CHRM1 308/4885 |
| US-10336769-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | CD44 4649/4885CYP3A4 1751/4885CHRM1 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.